These inhibitors pharmacologically modulate transporter function and, if they cross the BBB, could be used to treat AD, TBI, and other brain disorders associated with NMDA-mediated excitotoxicity due to increased SLC1A4-mediated D-serine efflux from inflammatory astrocytes. The gene discussed is SLC1A4; the disease is brain disorder.